AlzeCure Pharma
10.11.2021 08:21:31 CET | ACCESS Newswire | Press release
STOCKHOLM, SWEDEN / ACCESSWIRE / November 10, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - September 2021 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
"During the third quarter, we received positive data from our Phase I SAD clinical trial with the drug candidate ACD856, which is part of the NeuroRestore platform and which we are developing with a focus on Alzheimer's disease. We also received approval to test higher doses of the compound in the study, which is now underway, and after the end of the quarter we also started our Phase I MAD clinical trial with this compound. Regarding our ACD440 pain project, that belongs to the Painless platform and targets neuropathic pain, we have now submitted a request for a pre-IND meeting to the FDA for a planned Phase II study. We also focused on further developing new compounds in our preclinical pain project, TrkA-NAM, with the aim of choosing a drug candidate for the project in the second half of 2021. Thus we have once again closed the books on yet another positive and very active quarter at AlzeCure."
Martin Jönsson, CEO
Financial information for July - September, 2021
Figures in parentheses refer to the corresponding period of the previous year.
- Net sales during the period totaled SEK 0 thousand (0).
- Loss for the period totaled SEK -16,507 thousand (-21,455).
- Earnings per share, basic, totaled SEK -0.44 (-0.57).
- Total assets at the end of the period amounted to SEK 68,299 thousand (138,334).
- Cash and cash equivalents at the end of the period totaled SEK 62,672 thousand (132,976).
Financial information for January - September, 2021
Figures in parentheses refer to the corresponding period of the previous year.
- Net sales during the period amounted to SEK 0 thousand (0).
- The earnings for the period amounted to SEK -55,162 thousand (-53,646).
- Earnings per share before dilution amounted to SEK -1.46 (-1.42).
- Total assets amounted to SEK 68,299 thousand (138,334) at the end of the period.
- Cash and cash equivalents amounted to SEK 62,672 thousand (132,976) at the end of the period.
Significant events during the period January - September, 2021
- The company appointed Associate Professor Märta Segerdahl Storck, MD/PhD, to serve as Chief Medical Officer (CMO). Dr. Segerdahl took up the position on April 1 and is responsible for our clinical development activities. She is also part of AlzeCure's management group.
- In April the company received, slightly ahead of plan, positive and significant efficacy data from the phase Ib clinical trial with the drug candidate ACD440 for neuropathic pain. It was also well tolerated as a topical treatment.
- Eva Lilienberg was elected to serve on AlzeCure's Board of Directors at the Annual General Meeting on May 17. Eva further strengthens the company with her broad international regulatory and commercial experience.
- In July, a new publication on ACD856 was published in the journal Cells, describing the preclinical development of the substances within the NeuroRestore platform and results were presented. (Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction, Cells 2021 Jul23; 10 (8): 1871.)
- New data supporting targeting Trk receptors with ACD856 for treatment of Alzheimer's disease presented at Alzheimer's Association International Conference (AAIC) 2021 on July 26-30 in Denver USA.
- In August the company received approval from the Medical Products Agency to be able to give additional doses of ACD856 in the clinical phase I study (single ascending dose, SAD) with ACD856, as its good tolerability enables higher doses to be tested.
- In August the company received approval from the regulatory authorities in Sweden to begin the next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856 focused on Alzheimer's disease.
Significant events after the end of the period
- In October the first participant in the clinical phase I study (MAD) with the drug candidate ACD856 was dosed.
- The company presented the potential of the NeuroRestore project in depression at the European College of Neuropsychophamacology (ECNP 2021 on October 2-5 in Lisbon.
The full report is attached as PDF and is available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Attachments
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/672076/AlzeCure-Publishes-its-Interim-Report-for-January-September-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Synexis and Customate Collaborate to Advance Continuous Indoor Pathogen Control for the U.K. Poultry Industry5.10.2026 22:10:00 CEST | Press release
OVERLAND PARK, KS AND YORKSHIRE, ENGLAND / ACCESS Newswire / October 5, 2026 / Synexis®, LLC, the leader in touchless, continuous pathogen control technology, has announced a strategic collaboration with Customate Solutions, a family-owned engineering company and trusted provider of innovative manufacturing solutions with deep expertise across the poultry industry. The collaboration will bring Synexis patented DHP® technology to poultry producers throughout the United Kingdom and Ireland, helping hatcheries, poultry farms, processing facilities, and related operations strengthen indoor pathogen control while supporting modern biosecurity strategies. Poultry producers today face increasing pressure to maximize healthy hatch rates, improve chick quality, and strengthen biosecurity while reducing operational risk. Bacterial contamination on hatching eggs and throughout hatchery environments can directly impact hatchability, flock health, and production performance, making effective pathog
Chervon Names Claudio Chiappetta Vice President of Retail Sales for Chervon Canada5.10.2026 14:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 5, 2026 / Claudio Chiappetta joins Chervon as Vice President of Retail Sales for Chervon Canada; effective Monday, October 5, 2026, reporting to VP, MD Neil Harrison. A graduate of York University in Toronto, Chiappetta majored in business and marketing. He brings over 25 years of outdoor power equipment and power tool experience to Chervon as well as extensive knowledge of the Canadian home improvement and outdoor power equipment markets. Chiappetta launched his tool and outdoor career in 2003 at Black & Decker/DeWalt where he held various sales and marketing positions including cordless product manager for DeWalt Power Tools. Claudio joined TTI Milwaukee in 2008 where he was responsible for the launch of a series of Milwaukee cordless products into the Canadian market. He went on to build and manage the Ryobi outdoor power equipment portfolio along with multiple TTI power tool brands. "I am delighted to welcome Claudio to our Canadian senior
Chervon Names Daniel L. Abbott Director of Sales - Western U.S.A.5.10.2026 14:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 5, 2026 / Daniel L. Abbott joins Chervon as Director of Sales - Western U.S.A.; effective Monday, October 5, 2026, reporting to SVP Matt DeFeo. Abbott brings over 30 years of experience in the power tool, outdoor power equipment, and home improvement industry. As a graduate of Long Beach State, Abbott went on to serve for 4 years in the United States Airforce. Abbott then moved on to become a Home Depot Store Manager in Huntington Beach, California. Abbott then joined TTI/Milwaukee where he spent 24 years building, managing and leading an elite west coast-based sales team. Abbott was promoted through increasingly responsible positions until his final role as sales leader of over 700 salespeople. "Abbott is a proven and exceptional leader and mentor of high-potential sales talent," says SVP Matt DeFeo. "His obsessive focus on teaming up with key accounts at the store level has unleashed years of extraordinary growth in his areas of responsibili
Securitas Technology Releases 2027 Global Technology Outlook Report5.10.2026 14:00:00 CEST | Press release
UNIONTOWN, OH / ACCESS Newswire / October 5, 2026 / Securitas Technology, one of the world's largest electronic security companies, today announced the release of its 2027 Global Technology Outlook Report, offering organizations practical insights into the technologies, trends, and business priorities transforming the electronic security industry. Highly anticipated by security professionals across the globe - and now in its ninth annual edition - the Global Technology Outlook Report brings together perspectives from more than 16,000 end-user clients across 19 countries, independent research with more than 575 security decision-makers, 26 of the world's leading manufacturers, innovators, and Securitas Technology subject matter experts from around the world. The result is the industry's most comprehensive view of how security programs are evolving to address growing complexity, emerging risks, and rapidly changing technology. As security increasingly supports business resilience, operat
Chervon Names Peter J. Carlson Director of Sales for Strategic Accounts5.10.2026 14:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 5, 2026 / Peter J. Carlson joins Chervon as Director of Sales for Strategic Accounts effective Monday, October 5, 2026, reporting to SVP of Industrial and Commercial Sales, Jeff Campbell. Carlson brings over 27 years of power tool and outdoor product key account management experience to Chervon. A graduate of Bemidji State University in Bemidji, Minnesota; Carlson launched his career at Makita Power Tools in 1999. He progressed through a series of positions at Makita over the subsequent 10 years. In 2009, Carlson joined TTI/Milwaukee as a Senior National Account Manager. His career flourished as he was promoted through a series of increasingly responsible positions building and managing strategic key account business for TTI/Milwaukee. "Carlson is highly regarded in his ability to not only build the business but also to mentor, train and develop his people," SVP Campbell said. "His extensive experience at building store level and E-Commerce gr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom